Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aurelie Herault"'
Autor:
Kevin B. Walsh, Jeong M. Kim, Jovencio Borneo, Vincent Javinal, Aurelie Herault, Rajiv Jesudason, Genevive Hernandez, Judy Mak, Patricia E. de Almeida
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235e4e725cc5aa297c65f359b53e0f02
https://doi.org/10.1158/2326-6066.c.6550410
https://doi.org/10.1158/2326-6066.c.6550410
Autor:
Kevin B. Walsh, Jeong M. Kim, Jovencio Borneo, Vincent Javinal, Aurelie Herault, Rajiv Jesudason, Genevive Hernandez, Judy Mak, Patricia E. de Almeida
Supplementary tables 1-4 and supplementary figures 1-8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c71a4032796d19e9a2c56f6d9a9408
https://doi.org/10.1158/2326-6066.22543803.v1
https://doi.org/10.1158/2326-6066.22543803.v1
Autor:
Teemu T. Junttila, Kevin B. Walsh, Melissa R. Junttila, Klara Totpal, James Ziai, Alfonso Arrazate, Patricia De Almeida, Aurelie Herault, Judy Mak, Ryan Ybarra, Ji Li
Purpose:The response to cancer immune therapy is dependent on endogenous tumor-reactive T cells. To bypass this requirement, CD3-bispecific antibodies have been developed to induce a polyclonal T-cell response against the tumor. Anti-HER2/CD3 T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::714e2af02a06f65fb3c5f2f456132a1b
https://doi.org/10.1158/1078-0432.c.6527412.v1
https://doi.org/10.1158/1078-0432.c.6527412.v1
Autor:
Teemu T. Junttila, Kevin B. Walsh, Melissa R. Junttila, Klara Totpal, James Ziai, Alfonso Arrazate, Patricia De Almeida, Aurelie Herault, Judy Mak, Ryan Ybarra, Ji Li
Fig. S1. Subset analysis of tumor infiltrating and splenic CD8+ T cells after treatment with anti-HER2/CD3 TDB; Fig. S2. Anti-HER2/CD3 TDB increases intra-tumoral lymphocyte infiltration in Fo5 allograft model of HER2 overexpressing breast cancer wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::551368a9430de27f25df5a0aac223ce1
https://doi.org/10.1158/1078-0432.22470009
https://doi.org/10.1158/1078-0432.22470009
Autor:
Antonina V. Kurtova, Melanie Heinlein, Simon Haas, Lars Velten, Gerrit J. P. Dijkgraaf, Elaine E. Storm, Noelyn M. Kljavin, Soufiane Boumahdi, Patricia Himmels, Aurelie Herault, Andrew Mancini, Hartmut Koeppen, Monique Dail, Qingxiang Yan, Jianhuan Zhang, Ute Koch, Freddy Radtke, Zora Modrusan, Ciara Metcalfe, Robert Piskol, Frederic J. de Sauvage
Self-renewal and differentiation of stem and progenitor cells are tightly regulated to ensure tissue homeostasis. This regulation is enabled both remotely by systemic circulating cues, such as cytokines and hormones, and locally by various niche-conf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b308255afe28c772497cb21827be407c
http://edoc.mdc-berlin.de/21971/2/21971suppl.pdf
http://edoc.mdc-berlin.de/21971/2/21971suppl.pdf
Autor:
Kevin Walsh, Aurelie Herault, Genevive Hernandez, Patrícia de Almeida, Judy Mak, Jeong M. Kim, Rajiv Jesudason, Vincent Javinal, Jovencio Borneo
Publikováno v:
Cancer Immunology Research. 8:806-818
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bc6b07a7032555f678c5771e7435df3
https://doi.org/10.1158/2326-6066.cir-19-0360
https://doi.org/10.1158/2326-6066.cir-19-0360
Autor:
Patricia E, de Almeida, Judy, Mak, Genevive, Hernandez, Rajiv, Jesudason, Aurelie, Herault, Vincent, Javinal, Jovencio, Borneo, Jeong M, Kim, Kevin B, Walsh
Publikováno v:
Cancer immunology research. 8(6)
Antiangiogenic therapies that target the VEGF pathway have been used clinically to combat cancer for over a decade. Beyond having a direct impact on blood vessel development and tumor perfusion, accumulating evidence indicates that these agents also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60dc0eae081c1809b207fa41161dda9b
https://pubmed.ncbi.nlm.nih.gov/32238381
https://pubmed.ncbi.nlm.nih.gov/32238381
Autor:
Kevin Walsh, Melissa R. Junttila, Aurelie Herault, James Ziai, Judy Mak, Ji Li, Ryan Ybarra, Klara Totpal, Patrícia de Almeida, Teemu T. Junttila, Alfonso Arrazate
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(24)
Purpose: The response to cancer immune therapy is dependent on endogenous tumor-reactive T cells. To bypass this requirement, CD3-bispecific antibodies have been developed to induce a polyclonal T-cell response against the tumor. Anti-HER2/CD3 T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe436f2ea2ea6fa383024122e97d516f
https://pubmed.ncbi.nlm.nih.gov/29950350
https://pubmed.ncbi.nlm.nih.gov/29950350
Autor:
Yann Neuzillet, Xavier Paoletti, Slah Ouerhani, Pierre Mongiat-Artus, Hany Soliman, Hugues de The, Mathilde Sibony, Yves Denoux, Vincent Molinie, Aurélie Herault, May-Linda Lepage, Pascale Maille, Audrey Renou, Dimitri Vordos, Claude-Clément Abbou, Ashraf Bakkar, Bernard Asselain, Nadia Kourda, Amel El Gaaied, Karen Leroy, Agnès Laplanche, Simone Benhamou, Thierry Lebret, Yves Allory, François Radvanyi
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e48993 (2012)
TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR
Externí odkaz:
https://doaj.org/article/53f5b53e570340e18b559b078466bd8a